Englewood, Colorado-based foot and ankle medical device company Paragon 28, Inc. has announced its acquisition of Disior Oy. “The entire Disior team is very excited to join the Paragon 28 family,” said Disior CEO Anna-Maria Henell. “With this partnership, we have combined our talented teams and will bring a new standard of care to foot and ankle patients.
Paragon 28 Acquires Disior
1 min read Premium comments
#paragon28Secondary#disior
Paragon 28 paid $18 million for the company and agreed to up to $8 million in potential future payments at specific tech development and commercial milestones.
Leading medical device company Paragon 28 provides innovative ortho approaches and tools for foot and ankle ailments such as injuries, hammertoe, bunions, ankle and deformity. The company’s products are designed to improve outcomes, reduce complications and to make procedures as consistent and effective as possible. The company’s mission is “to continuously improve the outcomes and experiences of patients with foot and ankle conditions.”
Disior will be a large component of the Paragon 28’s SMART 28™ technologies, its initiative to modernize and improve all aspects of foot and ankle treatments through the use of advanced technologies. The SMART 28 system includes tools for surgical planning, intra-operative support, and postsurgical evaluation.
Based in Helsinki, Finland, Disior is a leading 3-D software company used for pre-operative planning, also focusing on foot and ankle issues. Disior has created a library of foot and ankle surgical modules to support orthopedic surgeons in diagnosing and creating surgical and follow up plans.
“Disior advances our previously communicated growth strategy to target unique technologies and will immediately accelerate our internal research and development efforts, plus provide surgeons unique pre-operative planning capabilities. Disior’s software combined with our broad product portfolio further differentiates us from the competition,” Paragon 28 Chairman and CEO Albert DaCosta said. “P28’s ultimate mission is to improve patient outcomes, and we believe our SMART 28™ ecosystem will modernize all aspects of foot and ankle surgery.”
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.